Table 2.

List of studies, in which all three methods: DSF, MST, and ITC were used

Studied target	Purpose	Other methods applied	Reference
Bromodomain-containing protein 4 (BRD4)	Characterize binding with a series of known and newly identified inhibitors	qPCR assay	(Karim et al. 2021)
The catalytic subunit of protein kinase CK2 (CK2α)	Screening for peptide inhibitors	Ligand-observed MS; NMR	(Winiewska-Szajewska et al. 2019)
Linker between the PYK2 kinase and FAT domains (KFL) in PYK2	Confirming and characterizing binding with calmodulin	SEC, AUC, and a number of additional biophysical approaches for different purposes	(Momin et al. 2022)
Bromodomains of EP300, CBP	Characterize binding with a series of intermediates and derivative of CCS1477		(Shendy et al. 2024)
FMDV capsids	Characterize binding with divalent transition metal ions	MALS	(Lin et al. 2021)
FAT domain from FAK and CH domain of α-parvin	Testing the affinity of the computationally predicted LD motifs		(Alam et al. 2020)
Intestinal mucin MUC2	Confirming copper binding	X-Ray, UV/Vis-competition titration,	(Reznik et al. 2022)
Bromodomain of BRD9	Screening for inhibitors	SPR, NMR, X-Ray	(Martin et al. 2016)
Elongation factor P (EF-P) from Acinetobacter baumannii	Confirming c-di-GMP binding		(Guo et al. 2022)
LMTK3 kinase domain	Screening for inhibitors	TR-FRET, kinase assay, CD	(Ditsiou et al. 2020)
Variants of the catalytic subunit of protein kinase CK2 (CK2α)	Characterize binding with the series of benzotriazoles		(Winiewska-Szajewska et al. 2024)
Aldehyde dehydrogenase 1A3 (ALDH1A3)	Confirming YD1701 binding	* CETSA instead of TSA	(Duan et al. 2022)